Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Impact of beta blockers on epithelial ovarian cancer survival.

Diaz ES, Karlan BY, Li AJ.

Gynecol Oncol. 2012 Nov;127(2):375-8. doi: 10.1016/j.ygyno.2012.07.102.

PMID:
22819786
2.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
3.

Impact of statin therapy on survival in epithelial ovarian cancer.

Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ.

Gynecol Oncol. 2008 Oct;111(1):102-5.

PMID:
20698078
4.

Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, Kusamura S.

BJOG. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x.

5.

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E.

Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Review.

PMID:
21324801
6.

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE.

J Surg Oncol. 2013 Feb;107(2):195-200. doi: 10.1002/jso.23171.

PMID:
22648987
7.

Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.

Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT.

Int J Gynecol Cancer. 2011 Jan;21(1):66-71. doi: 10.1097/IGC.0b013e3182013e2f.

PMID:
21178571
8.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
9.

Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.

Tang J, Liu DL, Shu S, Tian WJ, Liu Y, Zang RY.

Eur J Surg Oncol. 2013 Jul;39(7):786-91. doi: 10.1016/j.ejso.2013.02.006.

PMID:
23490332
10.

Obesity-associated adipokines correlate with survival in epithelial ovarian cancer.

Diaz ES, Karlan BY, Li AJ.

Gynecol Oncol. 2013 May;129(2):353-7. doi: 10.1016/j.ygyno.2013.02.006.

PMID:
23402904
11.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014.

PMID:
21917306
12.

Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.

Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Blumenson LE.

Gynecol Oncol. 1998 Nov;71(2):190-5.

PMID:
9826459
13.

Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.

Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, Hershman DL.

Obstet Gynecol. 2012 Oct;120(4):871-81.

PMID:
22996105
14.

Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.

Chao KC, Chen YJ, Juang CM, Lau HY, Wen KC, Sung PL, Fang FY, Twu NF, Yen MS.

Taiwan J Obstet Gynecol. 2013 Mar;52(1):81-4. doi: 10.1016/j.tjog.2012.10.003.

15.
16.

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.

Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM.

J Surg Oncol. 2000 Sep;75(1):24-30.

PMID:
11025458
17.

Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.

Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC.

Int J Gynecol Cancer. 2011 Aug;21(6):1013-7. doi: 10.1097/IGC.0b013e31821ce903.

PMID:
21792011
18.

Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.

Linasmita V, Wilailak S, Srisupundit S, Tangtrakul S, Bullangpoti S, Israngura N.

J Med Assoc Thai. 1998 Jan;81(1):10-6.

PMID:
9470316
19.

Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.

Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, Fujii S.

J Obstet Gynaecol Res. 2006 Dec;32(6):580-7.

PMID:
17100820
20.

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Dec;103(3):1083-90.

PMID:
16890277

Supplemental Content

Support Center